Understanding Wet Age-Related Macular Degeneration
Wet age-related macular degeneration is a progressive eye condition that affects the macula, the small but critical area at the center of the retina responsible for sharp, detailed vision. Unlike the more common dry form of AMD, wet AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood into the macula. This leakage damages the delicate photoreceptor cells and can lead to rapid, significant vision loss if left untreated.
Age-related macular degeneration affects more than 11 million people in the United States (BrightFocus Foundation, 2023). While wet AMD accounts for a smaller percentage of all AMD cases, it is responsible for the majority of severe vision loss associated with the disease. Receiving a diagnosis of wet AMD can understandably feel alarming, but effective treatments are available that can slow progression, stabilize vision, and in many cases improve sight.
Dry AMD progresses gradually as the macula thins with age and tiny protein deposits called drusen accumulate beneath the retina. Vision changes in dry AMD tend to develop slowly over months or years. Wet AMD, on the other hand, can cause sudden and noticeable changes in vision because of the abnormal blood vessel growth and leakage beneath the retina.
It is important to understand that dry AMD can progress to wet AMD over time. This is one of the key reasons why ongoing monitoring and regular eye examinations are so essential for anyone diagnosed with any form of macular degeneration. Early detection of the transition from dry to wet AMD allows treatment to begin promptly, which offers the best opportunity to preserve vision.
Wet AMD can present with several warning signs that may develop quickly. Being aware of these symptoms allows you to seek care without delay.
- Straight lines appearing wavy or distorted, such as door frames, text, or tile lines
- A blurry or dark area in the center of your vision
- Rapid worsening of central vision in one or both eyes
- Colors appearing less vivid or washed out compared to before
- Difficulty recognizing faces or reading, even with corrective lenses
If you notice any of these changes, contact your eye care team promptly. Time matters when it comes to wet AMD, and early intervention makes a meaningful difference in outcomes.
Who Is a Good Candidate for Treatment
If you have recently been diagnosed with wet AMD, you are likely a candidate for treatment. Your retina specialist will use detailed imaging of the back of your eye to confirm the diagnosis and determine the extent of the condition. These imaging tools provide a clear view of any abnormal blood vessels and fluid accumulation beneath the retina, helping your care team develop a treatment plan tailored to your specific situation.
Treatment is most effective when it begins early, before significant damage to the macula has occurred. Even if your vision loss feels mild at the time of diagnosis, starting treatment promptly helps protect the healthy retinal tissue that remains and gives you the strongest chance of maintaining functional vision over the long term.
Wet AMD is a chronic condition, and some patients experience periods where the disease becomes more active after a period of stability. If you have been previously treated for wet AMD and notice new symptoms such as increased distortion or worsening central vision, your care team may recommend resuming or adjusting your treatment plan. Ongoing monitoring ensures that any recurrence of abnormal blood vessel activity is caught early.
Patients who have been living with dry AMD and then develop signs of the wet form are important candidates for treatment. The transition from dry to wet AMD can occur gradually or suddenly. Your care team at Washington Eye Institute monitors for this transition during regular examinations, using advanced imaging to detect even subtle changes in the retina. If wet AMD is identified, treatment can begin right away.
Most patients with wet AMD can receive treatment regardless of age or other health conditions. The treatments used for wet AMD are delivered directly to the eye, which means they have minimal impact on the rest of the body. Your retina specialist will review your complete medical history and current medications to confirm that treatment is appropriate for you. Certain blood-thinning medications or other health factors may require coordination, but these rarely prevent treatment from moving forward.
How Wet AMD Treatment Works
To understand how treatment works, it helps to know what drives the disease. In wet AMD, the eye produces excessive amounts of a protein called vascular endothelial growth factor, commonly referred to as VEGF. Under normal circumstances, VEGF plays a helpful role in forming new blood vessels when the body needs them. In wet AMD, however, VEGF triggers the growth of fragile, abnormal blood vessels beneath the retina. These vessels leak fluid and blood, which damages the macula and leads to vision loss.
The primary goal of wet AMD treatment is to block this overproduction of VEGF, stopping the growth of abnormal blood vessels and reducing the leakage that harms the retina. By targeting the underlying cause of the disease, treatment can halt further damage and allow the retina to begin healing.
The most widely used and effective treatment for wet AMD involves injecting anti-VEGF medication directly into the eye. These medications bind to the excess VEGF protein and neutralize it, preventing it from stimulating abnormal blood vessel growth. Anti-VEGF therapy has improved the outlook for wet AMD patients over the past two decades, helping many people maintain and even recover vision that would have been lost without treatment.
The injection is performed in a clinical setting and takes only a few minutes. While the idea of an injection in the eye may sound daunting, the procedure is well-tolerated by most patients. Numbing drops are applied before the injection, so discomfort is typically minimal. Many patients report that the anticipation is far more stressful than the actual experience.
When anti-VEGF medication is injected into the vitreous, the gel-like substance that fills the inside of the eye, it diffuses through to the retina where it can act directly on the abnormal blood vessels. This targeted delivery allows the medication to reach the disease site in high concentration while minimizing effects elsewhere in the body. Over the weeks following an injection, the medication is gradually absorbed, which is why repeated treatments are necessary to maintain the therapeutic effect.
In some cases, your care team may recommend laser-based treatments as a complement to anti-VEGF therapy or when anti-VEGF injections alone are not sufficient. Photodynamic therapy involves injecting a light-sensitive medication into a vein in the arm. This medication collects in the abnormal blood vessels beneath the retina. A low-energy laser is then directed at these vessels, activating the medication and causing the abnormal vessels to close. Thermal laser treatment uses focused light energy to seal leaking blood vessels directly, though this approach is used selectively because it can affect nearby retinal tissue.
Types of Treatment Options
Several anti-VEGF medications are available for the treatment of wet AMD. While they differ in their specific molecular structures and duration of action, they all work by blocking VEGF activity in the eye. Your retina specialist will select the medication best suited to your condition based on factors such as the severity of your disease, how your eye responds to treatment, and how frequently injections may be needed.
Treatment typically begins with a series of monthly injections, often referred to as a loading phase. This initial course of treatment, usually consisting of three monthly injections, helps bring the disease under control quickly. After the loading phase, the frequency of injections may be adjusted based on how well your eye responds.
Newer anti-VEGF medications have been developed that remain active in the eye for longer periods, allowing some patients to go longer between injections. These extended-duration options can reduce the overall number of office visits and injections needed each year while maintaining the same level of disease control. Your care team will discuss whether an extended-duration medication may be appropriate for your situation.
Many retina specialists use a treatment strategy called treat-and-extend. With this approach, your injection interval is gradually lengthened as long as the disease remains stable. For example, you might start with monthly injections, then move to every six weeks, then every eight weeks, and potentially even longer intervals. If signs of disease activity return, the interval is shortened again. This personalized approach aims to find the longest safe interval between treatments for each individual patient.
- Reduces the total number of injections over time
- Maintains consistent disease control
- Adapts to each patient's unique response to treatment
- Decreases the frequency of office visits as the condition stabilizes
For some patients, combining anti-VEGF injections with other treatment modalities may offer additional benefits. Your care team may recommend photodynamic therapy alongside injections if certain types of abnormal blood vessel patterns are present. The decision to use combination therapy is based on the specific characteristics of your disease as revealed by diagnostic imaging, and your specialist will explain the rationale clearly before recommending this path.
Research into wet AMD treatment continues to advance. Newer approaches under investigation include sustained-release drug delivery systems designed to provide continuous anti-VEGF medication over extended periods, potentially reducing injection frequency even further. Other areas of research focus on targeting additional molecular pathways involved in abnormal blood vessel growth. Your care team stays informed of the latest developments and will discuss any new options that may be relevant to your care.
What to Expect During Treatment
Your initial visit will include a comprehensive retinal examination with advanced imaging. Optical coherence tomography, known as OCT, provides detailed cross-sectional images of the retina and can detect fluid accumulation with exceptional precision. Fluorescein angiography, which involves injecting a harmless dye into an arm vein and photographing the retina as the dye passes through its blood vessels, may also be performed to map the location and extent of abnormal vessels. These tests are painless and provide the information your care team needs to develop your treatment plan.
The injection itself is performed in a treatment room at the clinic. The process from start to finish typically takes less than fifteen minutes. Here is what you can expect during each visit.
- Your eye is cleaned with an antiseptic solution to minimize the risk of infection
- Numbing drops or a small injection of local anesthetic is applied to eliminate discomfort
- A small device may be used to gently hold the eyelids open during the procedure
- The medication is injected through the white part of the eye using a very fine needle
- You may feel a brief sensation of pressure, but significant pain is uncommon
- Antibiotic drops may be applied after the injection
Most patients are surprised by how quick and manageable the procedure is. It is normal to have questions or feel anxious before your first injection. Your care team is experienced in helping patients feel comfortable and will walk you through each step.
Following the injection, you may experience some mild eye redness, a gritty sensation, or the appearance of small floating spots in your vision. These effects are temporary and typically resolve within a day or two. Your care team will provide specific aftercare instructions, which may include using prescribed eye drops and avoiding rubbing the treated eye. You should be able to resume most normal activities the same day, though you will need someone to drive you home from your appointment.
At each follow-up visit, your care team will perform OCT imaging and possibly other tests to evaluate how well the treatment is working. They will look for reductions in fluid beneath the retina, changes in retinal thickness, and improvements in visual acuity. These objective measurements, combined with your own report of how your vision feels, guide decisions about the timing of your next treatment. Open communication with your care team about any changes in your vision between visits is important for optimal management of your condition.
Your Treatment Journey at Washington Eye Institute
Because wet AMD requires consistent monitoring and treatment, convenience matters. Washington Eye Institute offers retina care at our Greenbelt, Rockville, and Cumberland locations, making it easier for patients across the region to access specialized treatment without lengthy travel. Each location is equipped with advanced diagnostic imaging technology to support comprehensive retinal care.
Your treatment journey involves a team of skilled professionals working together. From the technicians who perform your imaging to the retina specialists who administer your injections, every member of your care team is focused on preserving and improving your vision. You will see consistent providers who understand your history and can track subtle changes in your condition over time. This continuity of care is especially important for a chronic condition like wet AMD.
One of the most critical factors in successful wet AMD treatment is consistency. Missed or delayed injections can allow the disease to become active again, potentially resulting in vision loss that may not be fully recoverable. Life circumstances can make it challenging to maintain a regular treatment schedule, and your care team understands this. If you need to reschedule an appointment, contact your clinic location promptly so that treatment gaps are minimized.
- Set reminders for upcoming appointments well in advance
- Arrange transportation ahead of time, since you should not drive immediately after treatment
- Communicate with your care team if scheduling conflicts arise
- Ask about treatment intervals and planning during each visit
Your care team may recommend that you monitor your vision at home between appointments using a simple tool called an Amsler grid. This grid of straight lines can help you detect subtle changes in your central vision, such as new areas of distortion or blurriness. If you notice any changes when using the Amsler grid, contact your care team right away rather than waiting for your next scheduled visit. Early detection of disease activity between appointments can make a significant difference in outcomes.
Wet AMD is a chronic condition that requires ongoing management, but with consistent treatment, many patients maintain useful central vision for years. Some patients experience meaningful improvement in visual acuity, particularly when treatment begins early. It is important to approach wet AMD management with realistic expectations. The primary goal of treatment is to stabilize the disease and preserve as much vision as possible. Your care team will be honest with you about what treatment can and cannot achieve for your specific situation, and they will adjust your plan as needed over time.
Frequently Asked Questions
Most patients report little to no pain during the injection. Before the procedure, numbing drops or a local anesthetic are applied to the eye, which significantly reduces sensation. You may feel a brief moment of pressure when the injection is administered, but this passes quickly. Many patients who were initially anxious about the procedure find that it is much more comfortable than they expected. If you are concerned about discomfort, let your care team know so they can take extra steps to help you feel at ease.
Treatment frequency varies from patient to patient. Most people begin with monthly injections for the first three months to bring the disease under control. After this loading phase, the interval between injections may be extended based on how your eye responds. Some patients eventually require injections every two to three months, while others may need them more or less frequently. Your care team will use imaging results and visual acuity measurements to determine the schedule that works best for you. Treatment is ongoing for most patients, as stopping injections can allow the disease to return.
In some cases, patients experience meaningful improvements in vision after beginning anti-VEGF therapy, particularly when treatment starts soon after symptom onset. As fluid is absorbed and the retina stabilizes, visual acuity can improve. However, any retinal tissue that has been scarred or damaged by the disease may not recover. This is why early detection and prompt treatment are so important. The primary aim of therapy is to halt further vision loss and stabilize your current level of sight, with improvement being a welcome possibility rather than a certainty.
Missing or delaying an injection can allow the abnormal blood vessels to become active again, leading to new leakage and potential vision loss. While a short delay of a few days is unlikely to cause significant harm in most cases, longer gaps between treatments increase the risk of disease progression. If you know you will miss an appointment, contact your care team as soon as possible to reschedule. Consistent treatment is one of the most important things you can do to protect your vision from further decline.
Anti-VEGF injections are considered safe and are well-tolerated by most patients. Common side effects include temporary redness at the injection site, mild discomfort, and small floating spots in vision. These typically resolve within a few days. Serious complications such as eye infection or retinal detachment are rare but possible. Your care team will discuss the signs to watch for after each injection, including sudden pain, significant vision decrease, or increasing redness. Contact your clinic immediately if you experience any of these symptoms after treatment.
Wet AMD is a chronic condition, and most patients require some form of ongoing treatment or monitoring for the long term. Some patients are able to extend the intervals between injections significantly over time, and a small number may eventually be able to pause treatment with careful monitoring. However, the disease can reactivate, so continued follow-up is essential even during periods of stability. Your care team at Washington Eye Institute will work with you to develop a long-term management plan that balances effective disease control with your quality of life and treatment preferences.